Targeted Therapy with Larotrectinib in NTRK Fusion Cancers: Results from the NCI-MATCH ECOG-ACRIN Trial

n

Precision oncology has transformed cancer treatment by focusing on the genetic drivers of tumors rather than on their site of origin alone. One of the most important breakthroughs in this field has been the development of therapies targeting NTRK gene fusions. Among these, Larotrectinib has emerged as a highly selective TRK inhibitor with significant clinical impact.

Understanding NTRK Gene Fusions

NTRK gene fusions occur when one of the NTRK genes (NTRK1, NTRK2, or NTRK3) becomes abnormally joined to another gene. This fusion leads to continuous activation of TRK proteins, driving tumor growth.

Although NTRK fusions are rare overall, they can occur across many tumor types, including:

• Lung cancer
• Colorectal cancer
• Thyroid cancer
• Sarcomas
• Pediatric tumors
• Rare solid tumors

Because these fusions are tumor-agnostic biomarkers, they can be treated with targeted therapy regardless of the cancer’s tissue origin.

What Is Larotrectinib?

Larotrectinib is a highly selective TRK inhibitor designed specifically to block TRK fusion proteins while sparing other kinases. This selectivity helps reduce off-target toxicity.

Larotrectinib has received regulatory approval in multiple regions for patients with NTRK fusion–positive solid tumors that are:

• Metastatic or unresectable
• Without satisfactory alternative treatment options

About the NCI-MATCH ECOG-ACRIN Trial

The National Cancer Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) trial is a precision oncology study that assigns patients to treatments based on genetic mutations rather than tumor location.

The ECOG-ACRIN Cancer Research Group conducted Subprotocol EAY131-Z1E to evaluate larotrectinib in patients whose tumors harbored NTRK gene fusions.

Key Features of the Trial

• Basket-style study design
• Included adults with advanced solid tumors
• Molecular screening identified NTRK fusions
• Patients received larotrectinib as targeted therapy

Key Results from Subprotocol EAY131-Z1E

The results demonstrated meaningful clinical activity of larotrectinib across various tumor types.

1. Objective Response Rate

A significant proportion of patients experienced tumor shrinkage. Responses were observed across different cancer types, reinforcing the tumor-agnostic effectiveness of TRK inhibition.

2. Duration of Response

Many responses were durable, with sustained disease control over time. This is particularly important in advanced cancers with limited treatment options.

3. Safety Profile

Larotrectinib was generally well tolerated. Most adverse events were mild to moderate in severity. The selective mechanism of action contributed to manageable toxicity.

Common side effects included:

• Fatigue
• Dizziness
• Elevated liver enzymes
• Gastrointestinal symptoms

Severe toxicities were relatively uncommon.

Why These Results Matter

The NCI-MATCH findings support several important conclusions:

1. Molecular testing is critical
   Identifying NTRK fusions can directly impact treatment decisions.
2. Tumor-agnostic therapy is effective
   Treatment based on genetic drivers can work across multiple cancer types.
3. Precision medicine is practical in real-world oncology
   National screening programs can successfully match patients to targeted therapies.

Clinical Implications

For oncologists:

• Comprehensive genomic profiling should be considered in advanced solid tumors.
• Rare biomarkers like NTRK fusions, though uncommon, can open the door to highly effective targeted treatments.

For patients:

• Genetic testing may uncover actionable mutations.
• Even rare alterations can have approved treatment options.
• Discuss molecular testing with your treating physician.

The Role of Biomarker Testing

Because NTRK fusions are rare in common cancers, broad molecular testing is often necessary to detect them. Methods include:

• Next-generation sequencing panels
• RNA-based fusion assays
• Comprehensive genomic profiling

Early identification can help avoid ineffective therapies and guide patients toward precision treatment.

Limitations of the Study

While results were promising, it is important to note:

• The number of NTRK-positive patients was relatively small because of the mutation’s rarity.
• Resistance mechanisms can develop over time.
• Long-term survival data continue to evolve.

Further research is ongoing to optimize sequencing strategies and manage acquired resistance.

Future Directions in TRK Inhibition

Second-generation TRK inhibitors are being developed to address resistance mutations. Combination strategies and earlier-line use are also areas of active investigation.

Precision oncology continues to move toward:

• Broader genomic screening
• Earlier biomarker identification
• More selective and safer targeted agents

Conclusion

The NCI-MATCH ECOG-ACRIN EAY131-Z1E subprotocol confirms that larotrectinib is an effective and well-tolerated targeted therapy for patients with NTRK fusion–positive cancers.

These findings reinforce the importance of molecular testing in modern oncology and demonstrate how tumor-agnostic therapies can provide meaningful benefit across diverse cancer types.

As precision medicine advances, identifying actionable genetic alterations remains a cornerstone of improving outcomes in advanced cancer.

This article is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made in consultation with a qualified oncologist.

References

1. Jhaveri KL, et al. Targeted Therapy with Larotrectinib in NTRK Fusion Cancers: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131-Z1E). JCO Precision Oncology. 2025. Click here

2. National Cancer Institute. NCI-MATCH Trial (Molecular Analysis for Therapy Choice). Click here

3. European Medicines Agency. Vitrakvi (larotrectinib) Product Information. Click here

4. Drilon A, et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. New England Journal of Medicine. 2018;378:731–739. Click here